PR86515

HOUSTON, Nov. 11, 2020 /PRNewswire=KYODO JBN/ --

  -- World Leader in Fibroblast Technology Advances Intellectual Property

     Position with their 250th Patent Filed Today

FibroGenesis, a Texas-based regenerative medicine company focused on tissue

regeneration and chronic disease reversal using Human Dermal Fibroblasts

(HDFs), today announced the filing of its 250th patent related to its

fibroblast cell therapy platform.

Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg    

Extending its world leading position as the authority on using fibroblasts to

treat chronic diseases, FibroGenesis expands its worldwide intellectual

property portfolio covering diseases such as COVID-19 ARDS, Degenerative Disc

Disease, Multiple Sclerosis, Parkinson's, Diabetes, Cancer, Chronic Traumatic

Encephalopathy (CTE), Pain and Muscular Dystrophy.

"Our scientific team is creating new opportunities for this "super cell,"

commented Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis.  

"Internal data and emerging third party validation, shows our proprietary

universal donor fibroblast-based product outperforms existing approaches.  

Our broad intellectual property establishes FibroGenesis as the gatekeeper for

anyone entering this space."

"As we continue to organically expand our intellectual property portfolio, we

are humbled by the equally expanding clinical capabilities of this unique cell

source," said Pete O'Heeron, Chief Executive Officer, FibroGenesis.  "Our new

clinical programs are providing evidence of a cell source superior to stem

cells and our proprietary position gives us the protection to continue our growth."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company

developing an innovative solution for chronic disease treatment using human

dermal fibroblasts. Currently, FibroGenesis holds 250 U.S. and international

issued patents/patents pending across a variety of clinical pathways, including

Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic

Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded

entirely by angel investors, FibroGenesis represents the next generation of

medical advancement in cell therapy.

Visit www.Fibro-Genesis.com .

SOURCE: FibroGenesis

CONTACT: info@fibro-genesis.com